The grant is one of only five projects supported in the UK by the Biotechnology and Biological Sciences Research Council (BBRSC) and will last eighteen months.
French biopharmaceutical company Erytech Pharma has entered a research collaboration with Queen’s University in Canada to advance the preclinical development of its eryminase programme, particularly for the treatment of arginase-1 deficiency.